PFOA, PFOS and PFHxS toxicokinetic considerations for the development of an in vivo approach for assessing PFAS relative bioavailability in soil
Date
2025
Authors
Juhasz, A.L.
Kastury, F.
Jones, R.
Seeborun, M.
Caceres, T.
Herde, C.
Cavallaro, M.
Dilmetz, S.
Hutchings, J.
Grebneva, Y.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Environment International, 2025; 195(109232)
Statement of Responsibility
Conference Name
Abstract
A Sprague-Dawley rat model was utilized to elucidate perfluorooctanoic acid (PFOA), perfluorooctanesulfonic acid (PFOS) and perfluorohexanesulfonic acid (PFHxS) toxicokinetics with a goal of developing an in vivo approach for quantifying PFAS relative bioavailability in impacted soil. Following single dose administration (gavage) of ∼ 0.2-2000 µg kg<sup>-1</sup> BW of PFOA, PFOS or PFHxS, differences in PFAS blood, organ and excreta concentrations were observed over 120 h although linear dose responses were determined for area under the blood plasma time curves (AUC; PFOA, PFHxS), liver accumulation (LA: PFOS) and urinary excretion (UE; PFOA, PFHxS). Oral and intravenous dose (∼20 µg kg<sup>-1</sup> body weight) comparisons highlighted the high absolute bioavailability of PFOA (AUC: 100.3 ± 23.4 %; UE: 94.7 ± 26.6 %), PFOS (LA: 102.9 ± 15.6 %) and PFHxS (AUC: 88.3 ± 15.1 %; UE: 90.9 ± 7.3 %). Two spiked (<sup>14</sup>C-PFOA: 4360 ± 218 µg kg<sup>-1</sup>) and two PFAS impacted soils (PFOS: 1880-2250 µg kg<sup>-1</sup>; PFHxS: 61.2-65.5 µg kg<sup>-1</sup>) were utilized to measure PFAS relative bioavailability in soil matrices. In all soils, PFAS relative bioavailability was > 86 % (PFOA: 87.0-90.9 %; PFOS: 86.1-90.4 %; PFHxS: 86.5-97.0 %) although the method could quantify bioavailability reductions (25.6-88.9 %) when hydrophobic and electrostatic interactions were enhanced through the addition of carbon-based amendments (5-10 % w/w).
School/Discipline
Dissertation Note
Provenance
Description
Data source: Supplementary data, https://doi.org/10.1016/j.envint.2024.109232
Access Status
Rights
Copyright 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)